RxDoctor Payments Data

Patrick Drummond, MD

Neurology · New York, NYNPI 1346651080

Payments from drug & device makers

$7,471in general payments, 2019–2025

Across 13 payments — averaging $574.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$7K
  • Boston Scientific$224
  • Merz Pharmaceuticals, LLC$172
  • AstraZeneca$117
  • Merz North America, Inc.$88
  • Abbott$47
  • plus $41 from 1 others

What the payments were for

  • Consulting fees$6,50087%
  • Food & beverage$97113%

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,471 in reported general payments places this provider in the 65th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$542,388
Medicare patients
523
Services billed
59,294

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate70$365,940
IngrezzaValbenazine Tosylate20$155,718
NeuproRotigotine100$112,820
RytaryCarbidopa/Levodopa58$84,688
GocovriAmantadine Hcl22$73,544
OngentysOpicapone72$70,918
BotoxOnabotulinumtoxina31$44,897
Droxidopa31$26,201
Carbidopa-LevodopaCarbidopa/Levodopa576$23,147
Carbidopa21$10,048
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone43$8,835
XeominIncobotulinumtoxina13$8,623
Carbidopa-Levodopa ErCarbidopa/Levodopa181$7,768
Entacapone21$6,849
AmantadineAmantadine Hcl55$4,613

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$6,782$44,89731 claims
Merz North America, Inc.Xeomin$88$8,62313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,623 neurology providers in New York.

Other neurology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →